FDA Expands Approval of Wilate® for Pediatric Von Willebrand Disease Patients Under 6 Years Old

Expansion of Wilate® Approval for Pediatric Patients

Octapharma USA has made significant strides in treating von Willebrand Disease (VWD) with the recent expanded approval from the U.S. Food and Drug Administration (FDA) for wilate® (von Willebrand Factor/Coagulation Factor VIII Complex). This crucial approval, granted on July 2, 2026, allows the use of wilate® for routine prophylaxis in children under six years of age, marking a pivotal moment in pediatric hematology.

Implications of the FDA Approval

The approval of wilate® gives pediatric patients with VWD access to preventive treatment, aiming to decrease the rate of bleeding episodes. VWD is recognized as the most common inherited bleeding disorder, typified by a deficiency in von Willebrand factor, which plays a key role in blood clotting. Although prior treatment methods were available for older patients, the lack of approved options for younger children has posed a significant challenge for healthcare providers.

Flemming Nielsen, President of Octapharma USA, expressed his enthusiasm about this milestone, noting that it brings much-needed solutions to pediatric hematologists who previously lacked FDA-approved treatments for young VWD patients. Routine prophylaxis will now align treatment options across different age groups, which is crucial for a comprehensive care protocol.

Clinical Research Behind the Approval

This expanded indication stems from promising results in the Phase 3 WIL-33 clinical trial (ClinicalTrials.gov ID NCT04953884), which specifically evaluated the safety and efficacy of VWF prophylaxis in very young children diagnosed with VWD. The trial enrolled 12 participants under the age of six, all of whom were experiencing severe forms of the disease. During this study, patients received wilate® administered two to three times a week at a recommended dose for a duration of 12 months.

The primary outcome measure was the total annualized bleeding rate (TABR) observed during prophylaxis. Results indicated a remarkably low annual bleeding rate (ABR) of 4.6, with an overwhelming 98.2% of the bleeding episodes classified as minor. Moreover, the efficacy in treating bleeding episodes was notable, with 95.6% of treated episodes resolved with a single infusion. These outcomes not only affirm the safety profile of wilate® but also demonstrate its capability to effectively manage bleeding in a pediatric population.

The WIL-33 study's findings reinforce earlier results from the WIL-31 study, which focused on older children and adults, showcasing that prophylactic treatment is equally effective across diverse age groups.

Safety and Efficacy Considerations

Both the WIL-33 and WIL-31 studies underscore the fact that wilate® is well-tolerated, with no significant thrombotic events or FVIII accumulation reported over the course of treatment. Dr. Akshat Jain, the principal investigator of the WIL-33 trial, emphasized the importance of this data in confirming that prophylactic treatment is safe, effective, and well-tolerated for pediatric patients, including those younger than six years.

Future Directions

Apart from this expanded FDA approval, wilate® had previously received an orphan drug designation, which ensures a seven-year market exclusivity from its approval date for the existing indications. This status highlights the significance of wilate® in providing necessary therapeutic interventions for individuals grappling with VWD, ultimately paving the way for future innovations in treatment.

About Octapharma

Octapharma, a leading global manufacturer in the human protein product sector, continues to advance the landscape of hematology through their commitment to research and patient care. After 40 years of dedication to developing therapies from human plasma, Octapharma's innovative approach aims to enhance the quality of lives globally, impacting patients suffering from critical illnesses.

In conclusion, the FDA's expanded approval of wilate® for young children marks a watershed moment for the management of von Willebrand Disease, ensuring that even the youngest patients now have access to crucial preventive care, bridging a critical gap in pediatric hematology.